Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

It is the treatment with the narrowest antimicrobial spectrum, it is inexpensive, and it is well studied for the prevention of rheumatic fever. Of all the cephalosporins, only first-generation ...

For further clarification, consult your healthcare provider. This medication is a broad-spectrum cephalosporin antibiotic, prescribed for serious infections such as respiratory tract infection ...